These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39150003)

  • 1. Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Sullivan MW; Graves S; Adkoli A; Zhou Q; Iasonos A; Ellenson LH; Chi DS; Aghajanian C; Liu YL; Sonoda Y; O'Cearbhaill RE; Weigelt B; Grisham RN
    Cancer; 2024 Aug; ():. PubMed ID: 39150003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Pitiyarachchi O; Ansell PJ; Coleman RL; Dinh MH; Holman L; Leath CA; Werner T; DiSilvestro P; Morgan M; Tew W; Lee C; Cunningham M; Newton M; Edraki B; Lim P; Barlin J; Spirtos NM; Tewari KS; Edelson M; Reid T; Carlson J; Friedlander M
    Gynecol Oncol; 2024 Aug; 187():221-226. PubMed ID: 38821039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
    Heitz F; Ataseven B; Staniczok C; Denkert C; Rhiem K; Hahnen E; Heikaus S; Moubarak M; Welz J; Dagres T; Vrentas V; Bommert M; Schneider S; Concin N; Harter P
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
    Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
    Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
    Romey M; Rodepeter F; Hattesohl A; Kaiser K; Teply-Szymanski J; Heitz F; Staebler A; Serra V; Grass A; Marmé F; Timms KM; Harter P; Llop-Guevara A; Kommoss S; Boekhoff J; Denkert C
    Mod Pathol; 2024 Apr; 37(4):100445. PubMed ID: 38341130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.
    Guarischi-Sousa R; Kroll JE; Bonaldi A; Pierry PM; Villela D; Souza CA; Silva JS; Bürger MC; Oliveira FA; de Paula MG; Meliso FM; de Almeida LG; Monfredini PM; de Oliveira AG; Milanezi F; Scapulatempo-Neto C; Yamamoto GL
    Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy.
    Rognoni C; Lorusso D; Costa F; Armeni P
    Adv Ther; 2024 Apr; 41(4):1385-1400. PubMed ID: 38329713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.
    Pepe F; Guerini-Rocco E; Fassan M; Fusco N; Vacirca D; Ranghiero A; Venetis K; Rappa A; Taormina SV; Russo G; Rebellato E; Munari G; Moreno-Manuel A; De Angelis C; Zamagni C; Valabrega G; Malapelle U; Troncone G; Barberis M; Iaccarino A
    J Clin Pathol; 2024 Jun; 77(7):478-485. PubMed ID: 37072171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023.
    Korsholm LM; Broecker V; Mirza MR; Rossing M
    Acta Oncol; 2024 Mar; 63():70-75. PubMed ID: 38482597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    Rabban JT; Chen LM; Devine WP
    Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis.
    Tsantikidi A; Papazisis K; Floros T; Gazouli M; Papadopoulou E; Tsaousis G; Nasioulas G; Mester A; Milan KP; Gozman B; Afrasanie V; Stanculeanu DL; Trifanescu O; Pescaru F; Militaru C; Papadimitriou C
    Oncol Lett; 2023 Nov; 26(5):480. PubMed ID: 37809048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Wehn AK; Qiu P; Lunceford J; Yarunin A; Cristescu R; Liu L; Roessler K; Bilke S; Day JR; Timms KM; Weichert W; Marton MJ
    Gynecol Oncol; 2024 May; 184():67-73. PubMed ID: 38290412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
    Capoluongo ED; Pellegrino B; Arenare L; Califano D; Scambia G; Beltrame L; Serra V; Scaglione GL; Spina A; Cecere SC; De Cecio R; Normanno N; Colombo N; Lorusso D; Russo D; Nardelli C; D'Incalci M; Llop-Guevara A; Pisano C; Baldassarre G; Mezzanzanica D; Artioli G; Setaro M; Tasca G; Roma C; Campanini N; Cinieri S; Sergi A; Musolino A; Perrone F; Chiodini P; Marchini S; Pignata S
    ESMO Open; 2022 Oct; 7(5):100585. PubMed ID: 36156447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    Frey MK; Pothuri B
    Gynecol Oncol Res Pract; 2017; 4():4. PubMed ID: 28250960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.